TrialBlood advances2026

A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Andrew M Brunner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.